Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TB Alliance publishes promising three-drug regimen data

This article was originally published in Scrip

Executive Summary

A new three-drug tuberculosis (TB) regimen eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to Phase IIb data published in The Lancet. PaMZ is comprised of two drugs that are not yet licensed for use against TB: pretomanid (formerly known as PA-824 and developed by TB Alliance) and the antibiotic moxifloxacin (developed by Bayer). The third component is another antibiotic, pyrazinamide, which is approved to treat TB. The therapy is intended for those patients whose TB infections are sensitive to the three drugs, including people with drug-sensitive and multidrug-resistant TB (MDR-TB). The PaMZ regimen appeared to be effective independent of HIV status. On the basis of these and other data, TB Alliance and its partners have launched a global Phase III trial named STAND (Shortening Treatment by Advancing Novel Drugs) in patients who are currently considered to have either drug-sensitive or MDR-TB. If successful, the PaMZ regimen could eliminate the need for injectable drugs and reduce the cost of MDR-TB therapy by more than 90% in those patients whose TB is sensitive to the three drugs.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028154

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel